Syndax Q1 revenue jumps on cancer drug sales

Syndax Pharmaceuticals

30/04/2026 21:29

Overview

US biopharma firm's Q1 revenue rose 224% yr/yr, driven by cancer therapy sales

Adjusted EPS and net loss for Q1 both beat analyst expectations

Revenue growth attributed to increased Revuforj uptake and higher Niktimvo collaboration revenue

Outlook

Company expects new Revuforj data from ongoing studies to be presented throughout 2026

Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and chronic GVHD

Syndax expects 2026 R&D plus SG&A expenses to be about $400 mln, excluding $50 mln stock compensation

Result Drivers

REVUFORJ UPTAKE - Co said Q1 revenue growth was driven by increased uptake of Revuforj in relapsed or refractory NPM1-mutated AML and KMT2Ar acute leukemia

KMT2A TRANSPLANT RATE - Co said nearly half of R/R KMT2A translocated patients are proceeding to stem cell transplant after Revuforj, up from prior estimates, which is expected to extend treatment duration

NIKTIMVO COMMERCIALIZATION - Co attributed Niktimvo revenue growth to expanded commercialization and clinical data supporting use in chronic GVHD

Company press release: ID:nGNXbrhhhy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Beat
-$0.48
-$0.58 (11 Analysts)
Q1 Net Income
Beat
-$42.67 mln
-$49.83 mln (9 Analysts)
Q1 Cash & Investments
$352.10 mln
Q1 Operating Expenses
$99.07 mln
Q1 Loss from operations
-$34.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $39.00, about 89% above its April 29 closing price of $20.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)